Editorially Independent Content, Financially Supported by
David Eichenbaum, MD, summarizes his ARVO presentation, which took a retrospective look at a number of pivotal trials in which patients received intravitreal anti-VEGF injections at quarterly intervals. He explains how patients do with this regimen, and talks about being able to detect and predict which patients can tolerate less frequent dosing.
AMD • Anti-VEGF • Intravitreal Injection
12 / 13 Series: 2018 ARVO Annual Meeting